Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NRXS
stocks logo

NRXS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NRXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.710
sliders
Low
2.50
Averages
High
2.50
Current: 2.710
sliders
Low
2.50
Averages
High
2.50
Craig-Hallum
Chase Knickerbocker
Buy
initiated
$7
2025-06-17
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$7
2025-06-17
initiated
Buy
Reason
Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target.
Craig-Hallum
Chase Knickerbocker
Buy
initiated
$7
2025-06-17
Reason
Craig-Hallum
Chase Knickerbocker
Price Target
$7
2025-06-17
initiated
Buy
Reason
As previously reported, Craig-Hallum analyst Chase Knickerbocker initiated coverage of Neuraxis with a Buy rating and $7 price target. The firm says this is a classic overlooked micro-cap medtech story that it believes will appear to be an overnight success story, though it was many years in the making. Neuraxis is introducing innovation into a space that does not get a lot of attention, namely pediatric functional abdominal pain. Craig-Hallum is highlighting the company's product IB-Stim as a potentially transformative therapy for pediatric functional abdominal pain disorders. The company targets a $3.7B market in severely debilitated patients, and the firm believes Neuraxis could very realistically reach $130M in revenue at just 4% penetration.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neuraxis Inc (NRXS.A) is -3.74, compared to its 5-year average forward P/E of -17.39. For a more detailed relative valuation and DCF analysis to assess Neuraxis Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-17.39
Current PE
-3.74
Overvalued PE
-5.06
Undervalued PE
-29.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.60
Undervalued EV/EBITDA
-1.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.42
Current PS
0.00
Overvalued PS
3.91
Undervalued PS
0.93
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 2459.92% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 2459.92% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NRXS News & Events

Events Timeline

(ET)
2025-12-01
07:22:00
NeurAxis Secures Veterans Affairs Contract Effective December 1, 2025
select
2025-11-12 (ET)
2025-11-12
08:26:43
Neuraxis Reveals Updated Medical Policy Coverage for Michigan
select
2025-11-11 (ET)
2025-11-11
07:02:23
Neuraxis Announces Q3 Revenue of $811K, Up from $667K Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
11-11SeekingAlpha
NeurAxis Prepares for 2026 Commercial Launch Amid Ongoing Double-Digit Growth and Approaching CPT Code Milestone

  • Management Insights: NeurAxis, Inc. is focused on executing its commercialization strategy for IB-Stim and RED, with a priority on securing medical policy coverage ahead of the new Category 1 CPT code effective January 1, 2026. The company is expanding its market opportunities and has seen positive payer momentum, with approximately 55 million covered lives.

  • Financial Performance: In Q3 2025, NeurAxis reported revenues of $811,000, a 22% increase year-over-year, and unit deliveries rose by 38%. However, operating expenses increased significantly, leading to an operating loss of $2.1 million, reflecting ongoing investments in sales and marketing.

  • Outlook and Growth Strategy: Management anticipates continued revenue growth into Q4 2025, driven by strong demand from healthcare providers and patients. They are implementing a three-pronged commercial plan for IB-Stim and addressing challenges in the adoption of RED due to changes in physician practice habits.

  • Risks and Concerns: The company acknowledges potential risks related to slow payer adoption and the challenges of changing physician practices for RED. Operating expenses and cash burn remain concerns, but management is focused on cost control while preparing for anticipated growth catalysts in 2026.

[object Object]
Preview
9.5
11-11NASDAQ.COM
NeurAxis Inc Reports Increased Losses in Q3
  • Earnings Overview: NeurAxis Inc reported a third-quarter loss of $2.12 million, an increase from a loss of $1.76 million in the same period last year.
  • Revenue Growth: The company's revenue rose by 20.9% to $0.81 million, compared to $0.67 million in the previous year.
[object Object]
Preview
9.5
11-11Newsfilter
NeurAxis Achieves Impressive Financial Performance in Q3 2025 with 22% Revenue Growth

  • Financial Performance: NeurAxis reported a 22% increase in revenues for Q3 2025, totaling $811 thousand, but also experienced a 27% rise in operating loss due to increased sales and marketing expenses.

  • FDA Clearances: The company received its first FDA clearance for treating pain in Functional Dyspepsia and expanded its IB-Stim device's indications to include patients aged 8-21, significantly broadening its market potential.

  • Operational Growth: NeurAxis expanded its total covered lives to approximately 55 million and secured a new CPT Category I code for PENFS procedures, effective January 1, 2026, enhancing reimbursement prospects.

  • Management Outlook: CEO Brian Carrico expressed optimism for substantial revenue growth in 2026, driven by expanded insurance coverage and increased demand for their proprietary PENFS technology.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neuraxis Inc (NRXS) stock price today?

The current price of NRXS is 2.71 USD — it has decreased -2.52 % in the last trading day.

arrow icon

What is Neuraxis Inc (NRXS)'s business?

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.

arrow icon

What is the price predicton of NRXS Stock?

Wall Street analysts forecast NRXS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is  USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neuraxis Inc (NRXS)'s revenue for the last quarter?

Neuraxis Inc revenue for the last quarter amounts to 811.41K USD, increased 21.72 % YoY.

arrow icon

What is Neuraxis Inc (NRXS)'s earnings per share (EPS) for the last quarter?

Neuraxis Inc. EPS for the last quarter amounts to -0.24 USD, decreased -4.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neuraxis Inc (NRXS)'s fundamentals?

The market is revising Downward the revenue expectations for NeurAxis, Inc. (NRXS) for FY2025, with the revenue forecasts being adjusted by -13.08% over the past three months. During the same period, the stock price has changed by 11.52%.
arrow icon

How many employees does Neuraxis Inc (NRXS). have?

Neuraxis Inc (NRXS) has 21 emplpoyees as of December 05 2025.

arrow icon

What is Neuraxis Inc (NRXS) market cap?

Today NRXS has the market capitalization of 28.87M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free